OSAKA -- Shionogi will start clinical trials for a COVID-19 nasal spray vaccine in fiscal 2022, the Japanese pharmaceutical company announced Tuesday, paving the way for an inoculation method that would benefit countries lacking medical staff.
Shionogi has a licensing agreement with HanaVax to develop a nasal spray vaccine using the venture's proprietary drug delivery system. The technology uses a polysaccharide substance to deliver the vaccine through the nose, inducing immunity in the respiratory system.
.jpg?width=700&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=394)
.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
